Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer

Ana M. Gonzalez-Angulo, A. Akcakanat, S. Liu, M. C. Green, J. L. Murray, H. Chen, S. L. Palla, K. B. Koenig, A. M. Brewster, V. Valero, N. K. Ibrahim, S. Moulder-Thompson, J. K. Litton, E. Tarco, J. Moore, P. Flores, D. Crawford, M. J. Dryden, W. F. Symmans, A. SahinS. H. Giordano, L. Pusztai, K. A. Do, G. B. Mills, G. N. Hortobagyi, F. Meric-Bernstam

Research output: Contribution to journalArticlepeer-review

60 Scopus citations

Fingerprint Dive into the research topics of 'Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences